VERONA PHARMA P/S (NASDAQ: VRNA) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
This table compares VERONA PHARMA P/S and Alnylam Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|VERONA PHARMA P/S||N/A||-42.87%||-37.51%|
This is a summary of current ratings and recommmendations for VERONA PHARMA P/S and Alnylam Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|VERONA PHARMA P/S||0||0||4||0||3.00|
VERONA PHARMA P/S currently has a consensus target price of $36.75, suggesting a potential upside of 160.64%. Alnylam Pharmaceuticals has a consensus target price of $141.15, suggesting a potential upside of 43.96%. Given VERONA PHARMA P/S’s stronger consensus rating and higher possible upside, equities analysts clearly believe VERONA PHARMA P/S is more favorable than Alnylam Pharmaceuticals.
Institutional and Insider Ownership
50.2% of VERONA PHARMA P/S shares are held by institutional investors. Comparatively, 90.2% of Alnylam Pharmaceuticals shares are held by institutional investors. 4.3% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility and Risk
VERONA PHARMA P/S has a beta of -2.98, indicating that its share price is 398% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500.
Earnings & Valuation
This table compares VERONA PHARMA P/S and Alnylam Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|VERONA PHARMA P/S||N/A||N/A||-$26.41 million||($2.41)||-5.85|
|Alnylam Pharmaceuticals||$89.91 million||109.62||-$490.87 million||($5.42)||-18.09|
VERONA PHARMA P/S has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than VERONA PHARMA P/S, indicating that it is currently the more affordable of the two stocks.
Alnylam Pharmaceuticals beats VERONA PHARMA P/S on 8 of the 14 factors compared between the two stocks.
About VERONA PHARMA P/S
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.